

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Clarity Pharmaceuticals Ltd
ABN	36 143 005 341

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Colin David Biggin
Date of last notice	4 July 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	n/a
Date of change	25 November 2025
No. of securities held prior to change	<ul style="list-style-type: none"> • 4,926,458 fully paid ordinary shares • 837,855 options exercisable at \$0.508 each on or before 24 November 2027 • 557,393 options exercisable at \$0.793 each on or before 24 November 2028 • 371,595 options exercisable at \$0.721 each on or before 24 November 2028 • 99,679 options exercisable at \$5.505 each on or before 20 November 2029 • 186,239 options exercisable at \$5.005 each on or before 20 November 2029
Class	Options

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Number acquired	<ul style="list-style-type: none"> • 199,909 options exercisable at \$2.30 each on or before 1 July 2030 (Component A) • 287,530 options exercisable at \$2.30 each on or before 1 July 2030 (Component B)
Number disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	<ul style="list-style-type: none"> • Component A: Indicative value of \$267,878 using a Black-Scholes valuation using the 5-day VWAP of shares at 30 June 2025. • Component B: Indicative value of \$519,997 using a Monte Carlo simulation using the 5-day VWAP of shares at 30 June 2025.
No. of securities held after change	<ul style="list-style-type: none"> • 4,926,458 fully paid ordinary shares • 837,855 options exercisable at \$0.508 each on or before 24 November 2027 • 557,393 options exercisable at \$0.793 each on or before 24 November 2028 • 371,595 options exercisable at \$0.721 each on or before 24 November 2028 • 99,679 options exercisable at \$5.505 each on or before 20 November 2029 • 186,239 options exercisable at \$5.005 each on or before 20 November 2029 • 487,439 options exercisable at \$2.30 each on or before 1 July 2030
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of options following approval at the Company's 2025 Annual General Meeting

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	n/a
Nature of interest	n/a
Name of registered holder (if issued securities)	n/a

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Date of change	n/a
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	n/a
Interest acquired	n/a
Interest disposed	n/a
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	n/a
Interest after change	n/a

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	n/a
If prior written clearance was provided, on what date was this provided?	n/a

⁺ See chapter 19 for defined terms.

For personal use only